Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug687 | Breath Biopsy Wiki | 1.00 |
drug1211 | Cyclophosphamide injection Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
Tubercular meningitis occurs in around 10% of those with extrapulmonary tuberculosis and is a major cause of mortality and morbidity. Inspite of effective Anti-tubercular drugs, still around 30% of patients develop complications due to arachnoiditis such as spinal tubercular radiculomyelitis, optico-chiasmatic arachnoiditis, development of new tuberculomas after starting therapy etc. which are probably immune mediated inflammatory responses due to paradoxical reaction to ATT. The management of arachnoiditis is far from satisfactory. High dose methylprednisolone, intrathecal hyaluronic acid, thalidomide have been tried in small case series and case reports. However, the results have not been satisfactory. There are two published reports of cyclophosphamide usage in TBM related vasculitis and stroke The investigators tried cyclophosphamide in four patients after consent, and found remarkable improvement in all of them. (Under peer review) In order to test this hypothesis, a randomized controlled trial is needed.
Description: To compare the proportion of patients who attain functional independence (mRS-modified Rankin scale 0-2) 6 months after cyclophosphamide therapy for proliferative arachnoiditis refractory to corticosteroids and standard Anti-tubercular therapy in CNS tuberculosis to those who receive placebo.
Measure: Functional independece at 6 months Time: 6 monthsDescription: To compare the proportion of patients who attain independent ambulation 6 months after cyclophosphamide therapy for proliferative arachnoiditis refractory to corticosteroids and standard Anti-tubercular therapy in CNS tuberculosis to those who receive placebo.
Measure: Independent ambulation Time: 6 monthsDescription: To compare the proportion of patients improving from mRS ≥3 to mRS ≤2 six months post cyclophosphamide therapy
Measure: Improvement in modified Rankin scale Time: 6 monthsDescription: To compare the proportion of patients who attain atleast 2 points improvement on Snellen's chart in visual acuity 6 months after cyclophosphamide therapy for proliferative arachnoiditis refractory to corticosteroids and standard Anti-tubercular therapy in CNS tuberculosis to those who receive placebo.
Measure: Improvement in visual acuity (1) Time: 6 monthsDescription: To compare proportion of patients who attain atleast two point improvement on a semiquantitative visual acuity measurement in those who have visual acuity less than 1/60 on snellen's chart (finger counting at 1 m, hand movements at 1 m, perception of light, no perception of light considered as discrete points below 1/60 vision on standard Snellen's chart) 6 months after cyclophosphamide therapy
Measure: Improvement in visual acuity (2) Time: 6 monthsDescription: To compare proportion of patients improving from visual acuity of <3/60 in the better eye to 3/60 or more 6 months post cyclophosphamide therapy
Measure: Improvement in visual acuity (3) Time: 6 monthsDescription: To compare the proportion of patients who attain improvement in bladder/bowel function 6 months after cyclophosphamide therapy for proliferative arachnoiditis refractory to corticosteroids and standard Anti-tubercular therapy in CNS tuberculosis to those who receive placebo..
Measure: Improvement in sphincter function Time: 6 monthsDescription: Shift analysis pre-and 6 months post therapy in terms of change in mRS
Measure: Change in mRS Time: 6 monthsDescription: Comparing Global patient well being as assessed by SF-36 pre and 6 months post cyclophosphamide therapy
Measure: Patient well being Time: 6 monthsDescription: Occurrence of life threatening infections necessitating cessation of therapy upto 3 months post cyclophosphamide therapy
Measure: Life threatening infections Time: 3 monthsDescription: Occurrence of infections needing hospitalization or intravenous antibiotic/antiviral/anti-fungal therapy upto 3 months post cyclophosphamide therapy
Measure: Infections needing hospitalization Time: 3 monthsDescription: Flare up of underlying tuberculosis upto 3 months post cyclophosphamide therapy
Measure: Flare up of TB Time: 3 monthsDescription: Occurrence of Grade III cytopenias defined as per common terminology criteria for adverse events v 5.0 upto 6 weeks post cyclophosphamide therapy
Measure: Cytopenias Time: 6 weeksDescription: Grade III transaminitis as per CTCAE v 5.0 upto 6 weeks post cyclophosphamide therapy
Measure: Transaminitis Time: 6 weeksDescription: Occurrence of hemorrhagic cystitis upto 2 weeks post cyclophosphamide therapy
Measure: Hemorrhagic cystitis Time: 2 weeksDescription: Any other significant adverse effect
Measure: Adverse effects Time: 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports